Niridazole (Ambilhar) and three other newly synthesized nitrothiazole derivatives were highly active against 19 microaerophilic campylobacters (minimum concentration required to inhibit 50% of strains [MIC50], 0.0075 to 0.015 mg/liter). There were, however, considerable differences in the susceptibility among strains tested, and one nitrothiazole derivative was rather inactive (MIC50, 2 mg/liter). Nitroimidazole derivatives, such as metronidazole and tinidazole, were less active (MIC50, 2 and 4 mg/liter, respectively). The nitrofuran derivatives, such as nitrofurazone and nitrofurantoin, were also less active (MIC50, 1 mg/liter). Niridazole and another potent nitrothiazole derivative killed the campylobacters rapidly at low concentrations. In contrast, much higher concentrations of metronidazole were required to achieve bactericidal values.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC179952PMC
http://dx.doi.org/10.1128/AAC.26.4.498DOI Listing

Publication Analysis

Top Keywords

mic50 mg/liter
12
nitrothiazole derivative
8
active mic50
8
antibacterial activities
4
nitrothiazole
4
activities nitrothiazole
4
nitrothiazole campylobacter
4
campylobacter jejuni
4
jejuni campylobacter
4
campylobacter coli
4

Similar Publications

Activity of Amphotericin B Formulations and Voriconazole, Alone or in Combination, against Biofilms of and Fusarium spp.

Antimicrob Agents Chemother

October 2021

Infectious Diseases Unit, 3rd Department Pediatrics, Basic and Translational Research Unit, Special Unit for Biomedical Research and Education, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessalonikigrid.4793.9 and Hippokration General Hospital, Thessaloniki, Greece.

and Fusarium species are emerging opportunistic pathogens, causing invasive fungal diseases in humans, particularly in immunocompromised patients. Biofilm-related infections are associated with increased morbidity and mortality. Here, we assessed the ability of Scedosporium apiospermum and Fusarium solani species complex (FSSC) isolates to form biofilms and evaluated the efficacy of deoxycholate amphotericin B (D-AMB), liposomal amphotericin B (L-AMB), and voriconazole (VRC), alone or in combination, against mature biofilms.

View Article and Find Full Text PDF

Extended-spectrum-beta-lactamase (ESBL)-producing continue to pose a major threat to human health worldwide. Given the limited therapeutic options available to treat infections caused by these pathogens, identifying additional effective antimicrobials or revisiting existing drugs is important. Ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae containing CTX-M-type ESBLs or AmpC, in addition to narrow-spectrum OXA and SHV enzymes, were selected from blood culture isolates obtained from the MERINO trial.

View Article and Find Full Text PDF

Previously, we reported the potent activity of a novel spiropyrimidinetrione, zoliflodacin, against isolates collected in 2013 from symptomatic men in Nanjing, China. Here, we investigated trends of susceptibilities to zoliflodacin in 986 isolates collected from men between 2014 and 2018. isolates were tested for susceptibility to zoliflodacin and seven other antibiotics.

View Article and Find Full Text PDF

Olorofim is a novel antifungal drug in phase 2 trials. It has shown promising activity against various molds, except for Mucorales. Initially, we observed a broad range of EUCAST MICs for Here, we explored the MIC variability in more detail and prospectively investigated the susceptibility of contemporary clinical mold isolates, as population data are needed for future epidemiological cutoff (ECOFF) settings.

View Article and Find Full Text PDF

Activity of Manogepix against Multidrug-Resistant and Panresistant Candida auris from the New York Outbreak.

Antimicrob Agents Chemother

October 2020

Mycology Laboratory, Wadsworth Center, New York State Department of Health, Albany, New York, USA

An ongoing outbreak in the New York metropolitan area is the largest recorded to date in North America. Laboratory surveillance revealed NY isolates are resistant to fluconazole, with variable resistance to other currently used broad-spectrum antifungal drugs, and that several isolates are panresistant. Thus, there is an urgent need for new drugs with a novel mechanism of action to combat the resistance challenge.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!